ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > waiting

<< Previous

Bullboard Posts

Next >>

Comment by azzymaaon Mar 21, 2022 5:26pm

78 Views

Post# 34532694

RE:RE:waiting

David - True there are much bigger fish in the pond and I also believe promis won't be the one selling alzheimers drugs anytime soon or in the future. Either they come up with something and sell it or end of going back and forth on their deadlines. I have my sell at 0.14 so atleast I can make a few bucks and leave, as of right now I am pretty much dead even so I am not affected as some the other long term bag holders on this forum.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks